EDCTP
![Image ohne Titel](https://cdn.lmu-klinikum.de/00ad772884f957c6/a973efdb6f6a/v/17bc8951a748/GeneralAssembly_20171109_web.jpg)
![Image ohne Titel](https://cdn.lmu-klinikum.de/4605f2fb0a979887/ad93c2080203/v/3181cfa2267e/EDCTP_Logo_red-copy.jpg)
![Image ohne Titel](https://cdn.lmu-klinikum.de/2ec788725e015812/253e12cfd618/v/80ca6c1805b1/European-AU-FLAG-RAPID-COPY.jpg)
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials.
EDCTP’s second programme (2014-2024) supports all clinical trial phases (I-IV) including health services optimisation research. Research and regulatory capacity development remain integrated in the research funding strategy in order to strengthen the conditions for conducting clinical research in sub-Saharan Africa.
The EDCTP programme is executed through partnerships between European and African institutions and researchers in collaboration with the pharmaceutical industry and like-minded organisations.
The programme is implemented as part of the European Framework Programme for Research and Innovation, Horizon 2020, and governed by the participating African and European countries.